FBXO3

Across TCGA pan-cancer cohorts, FBXO3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO3 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher FBXO3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, UCEC, and HNSC are the cancer types where FBXO3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
UCEC	DFS	Median	All	0.933	0.618	.020	22	view →
HNSC	OS	Median	II,III,IV	0.086	0.711	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO3–SCLC (OS)

Open the SCLC breakdown →